

MEDICAL PHARMACIES NEW DRUGS

Drug Information and News for Health Care Providers

April 2016

TRULICITY™ (DULAGLUTIDE SOLUTION FOR INJECTION)

SUPPLIED AS: 0.75 MG/0.5 ML AND 1.5 MG/0.5 ML IN SINGLE-USE PREFILLED SYRINGE AND SINGLE-USE PREFILLED PEN¹

INDICATION FOR USE AND GOAL(S) OF THERAPY

The goal of Trulicity™ is to reach blood glucose control targets without causing adverse effects, including hypoglycemia.

Trulicity™ is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is indicated once weekly for adults (≥ 18 years of age) with type 2 diabetes to improve blood glucose control, in combination with:

- Diet and exercise
- Metformin
- Metformin and a sulfonylurea
- Prandial insulin with metformin

CONTRAINDICATIONS

Trulicity™ is contraindicated in residents who have:

- A personal or family history of medullary thyroid carcinoma (MTC) or
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)

DOSE & ADMINISTRATION

The recommended initiating dose of Trulicity™ is 0.75 mg once weekly, administered subcutaneously. The dose may be increased to the maximum recommended dose of 1.5 mg once weekly. No dose adjustment is required in residents with renal impairment or hepatic insufficiency.

WHAT TO MONITOR AND REPORT TO THE HEALTHCARE TEAM

Monitor the resident for the following:

- Signs of thyroid tumours (e.g., a mass in the neck, dysphagia, dyspnea, or persistent hoarseness)
- Pulse for increasing heart rate (Trulicity™ may also increase risk of atrial fibrillation and caution is, therefore, warranted in residents with a history of atrial fibrillation, structural heart disease, pre-existing conduction system abnormalities, ischemic heart disease, or cardiomyopathies.)
- Blood glucose for hypoglycemia

Please refer to Trulicity™ product monograph for more comprehensive information, including warnings and precautions.



Other drug products in this category (GLP-1 receptor agonists) that are currently available include:

- Liraglutide (Victoza®)
- Exenatide (Byetta®)

Reference:

1. Trulicity™ Product Monograph. Eli Lilly Canada Inc. November 2015.